https://doi.org/10.1056/nejmoa1311084
T
Tetsuya Eto
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
486
Papers
8.3K
Citations
47
h-index
174
i10-index
Tetsuya Eto is an academic researcher from Hamanomachi Hospital. The author has contributed to research in topics: Hematopoietic Stem Cell Transplantation & Acute Myeloid Leukemia Research & Acute Lymphoblastic Leukemia research. The author has an h-index of 47, co-authored 414 publications.
ORCID: 0000-0002-2630-493XPapers by this author
worksGenetic Variants in C5 and Poor Response to Eculizumab
2014 · New England Journal of Medicine · 392 citations
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
2024 · Journal of Clinical Oncology · 167 citations
https://doi.org/10.1200/jco.23.02474
Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy
2015 · Journal of Hematology & Oncology · 32 citations
https://doi.org/10.1186/s13045-015-0201-x
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
2018 · ESMO Open · 28 citations
https://doi.org/10.1136/esmoopen-2018-000354
The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation
2018 · Hematological Oncology · 27 citations
https://doi.org/10.1002/hon.2558
Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
2017 · Cancer Chemotherapy and Pharmacology · 15 citations
https://doi.org/10.1007/s00280-017-3422-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat